CDKN1A and acute myeloid leukemia: BKM120, a morpholinopyrimidine derivative, has been confirmed to abrogate the activity of the PI3K/Akt/mTOR signaling, promoting cell growth arrest in AML cells [22] and impair the viability of AML cells through inducing p21-mediated G2/M cell cycle arrest and reducing expression of NF-κB anti-apoptotic proteins [23].